Search Results - "Ladoire, S"

Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? by Apetoh, L., Ladoire, S., Coukos, G., Ghiringhelli, F.

“…Recent clinical trials revealed the impressive efficacy of immunological checkpoint blockade in different types of metastatic cancers. Such data underscore…”
Get full text

Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists by Yamazaki, T, Hannani, D, Poirier-Colame, V, Ladoire, S, Locher, C, Sistigu, A, Prada, N, Adjemian, S, Catani, J PP, Freudenberg, M, Galanos, C, André, F, Kroemer, G, Zitvogel, L

“…Immunogenic cell death induced by anticancer chemotherapy is characterized by a series of molecular hallmarks that include the exodus of high-mobility group…”
Get full text

Human FOXP3 and cancer by Martin, F, Ladoire, S, Mignot, G, Apetoh, L, Ghiringhelli, F

“…FOXP3 is a transcription factor necessary and sufficient for induction of the immunosuppressive functions in regulatory T lymphocytes. Its expression was first…”
Get full text

Liver X receptor β activation induces pyroptosis of human and murine colon cancer cells by Derangère, V, Chevriaux, A, Courtaut, F, Bruchard, M, Berger, H, Chalmin, F, Causse, S Z, Limagne, E, Végran, F, Ladoire, S, Simon, B, Boireau, W, Hichami, A, Apetoh, L, Mignot, G, Ghiringhelli, F, Rébé, C

“…Liver X receptors (LXRs) have been proposed to have some anticancer properties, through molecular mechanisms that remain elusive. Here we report for the first…”
Get full text

Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies by Apetoh, L, Végran, F, Ladoire, S, Ghiringhelli, F

“…Accumulating evidence suggests that the success of some anticancer therapies not only relies on their direct cytotoxicity on tumor cells but also on their…”
Get more information

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) by Bamias, A., Tzannis, K., Harshman, L.C., Crabb, S.J., Wong, Y.-N., Kumar Pal, S., De Giorgi, U., Ladoire, S., Agarwal, N., Yu, E.Y., Niegisch, G., Necchi, A., Sternberg, C.N., Srinivas, S., Alva, A., Vaishampayan, U., Cerbone, L., Liontos, M., Rosenberg, J., Powles, T., Bellmunt, J., Galsky, M.D.

“…Cisplatin-based combination chemotherapy is the standard treatment of advanced urinary tract cancer (aUTC), but 50% of patients are ineligible for cisplatin…”
Get full text

Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer by Poumeaud, F., Morisseau, M., Cabel, L., Gonçalves, A., Rivier, C., Trédan, O., Volant, E., Frenel, J.-S., Ladoire, S., Jacot, W., Jamelot, M., Foka Tichoue, H., Patsouris, A., Teixeira, L., Bidard, F.-C., Loirat, D., Brunet, M., Levy, C., Bailleux, C., Cabarrou, B., Deleuze, A., Uwer, L., Deluche, E., Grellety, T., Franchet, C., Fiteni, F., Bischoff, H., Vion, R., Pagliuca, M., Verret, B., Bécourt, S., Reverdy, T., de Nonneville, A., Dalenc, F.

“…Background Current guidelines recommend that patients with HER2-low metastatic breast cancer (MBC) receive sequentially two antibody–drug conjugates (ADCs):…”
Get full text

Tumor lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer: The LYMPHOREC study by Mirjolet, C., Charon-Barra, C., Ladoire, S., Arbez-Gindre, F., Bertaut, A., Ghiringhelli, F., Leroux, A., Peiffert, D., Borg, C., Bosset, J. F., Créhange, G.

“…Introduction: Some studies have suggested that baseline tumor-infiltrating-lymphocytes (TILs), such as CD8+ and FoxP3+ T-cells, may be associated with a better…”
Get full text

Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer by Guiu, Boris, Petit, Jean Michel, Bonnetain, Franck, Ladoire, Sylvain, Guiu, Séverine, Cercueil, Jean-Pierre, Krausé, Denis, Hillon, Patrick, Borg, Christophe, Chauffert, Bruno, Ghiringhelli, François

“…Adipose tissue releases angiogenic factors that may promote tumour growth. To determine whether body mass index (BMI), subcutaneous fat area (SFA) and visceral…”
Get more information

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy by Fizazi, K., Ulys, A., Sengeløv, L., Moe, M., Ladoire, S., Thiery-Vuillemin, A., Flechon, A., Guida, A., Bellmunt, J., Climent, M.A., Chowdhury, S., Dumez, H., Matouskova, M., Penel, N., Liutkauskiene, S., Stachurski, L., Sternberg, C.N., Baton, F., Germann, N., Daugaard, G.

“…This phase II study was conducted to assess clinical efficacy of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer…”
Get full text

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) by Bamias, A., Tzannis, K., Harshman, L.C., Crabb, S.J., Wong, Y.-N., Kumar Pal, S., De Giorgi, U., Ladoire, S., Agarwal, N., Yu, E.Y., Niegisch, G., Necchi, A., Sternberg, C.N., Srinivas, S., Alva, A., Vaishampayan, U., Cerbone, L., Liontos, M., Rosenberg, J., Powles, T., Bellmunt, J., Galsky, M.D.

Get full text

Brain metastases response to nivolumab in patients with renal cell carcinoma (RCC): Prospective analysis from the GETUG-AFU 26 (NIVOREN) trial by Flippot, R., Dalban, C., Laguerre, B., Borchiellini, D., Gravis, G., Negrier, S., Chevreau, C.M., Joly, F., Geoffrois, L., Ladoire, S., Mahammedi, H., Tantot, F., Escudier, B., Albiges, L.

Get full text

T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival by Ladoire, S, Arnould, L, Mignot, G, Apetoh, L, Rébé, C, Martin, F, Fumoleau, P, Coudert, B, Ghiringhelli, F

“…Background: In HER2-overexpressing breast cancer, accumulating preclinical evidences suggest that some chemotherapies, like trastuzumab, but also taxanes, are…”
Get full text

FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial by Ladoire, S., Mignot, G., Dalban, C., Chevriaux, A., Arnould, L., Rébé, C., Apetoh, L., Boidot, R., Penault-Llorca, F., Fumoleau, P., Roché, H., Spielmann, M., Levy, C., Lortholary, A., Eichler, F., Mesleard, C., Bonnetain, F., Ghiringhelli, F.

“…Predictive markers of response to chemotherapy are lacking in breast cancer patients. Forkhead Box Protein 3 (FOXP3) is an anti-oncogene whose absence in…”
Get full text

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer by Guiu, S, Gauthier, M, Coudert, B, Bonnetain, F, Favier, L, Ladoire, S, Tixier, H, Guiu, B, Penault-Llorca, F, Ettore, F, Fumoleau, P, Arnould, L

“…Background: We analysed whether the level of human epidermal growth factor receptor-2 (HER-2) amplification significantly influenced either pathological…”
Get full text

Which PSA Endpoint Best Predicts Disease-Free Survival in Prostate Cancer Patients Treated With Exclusive Radiation Therapy Combined With Hormones? by Thouant, M, Bertaut, A, Pommier, P, Maingon, P, Martin, E, Quivrin, M, Vulquin, N, Ladoire, S, Cormier, L, Carrie, C, Crehange, G

Get full text

The Relationship Between the Occurrence of Bone Metastases and Dose/Volume of Prior Prostate Radiation Therapy in Patients With Localized Prostate Cancer by Crehange, G, Laporte, G, Dalban, C, Martin, E, Cochet, A, Cormier, L, Mirjolet, C, Desmoulins, I, Ladoire, S, Maingon, P

Get full text

2009 Tumoral lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer as a prognostic factor for survival: The LYMPHOREC study by Mirjolet, C, Charon-barra, C, Arbez-gindre, F, Gauthier, M, Maingon, P, Barthod, Z, Leroux, A, Merlin, J.L, Peiffert, D, Dalban, C, Ladoire, S, Bosset, J.F, Crehange, G

Get full text

2607 Predicting venous thromboembolism (VTE) in metastatic urothelial tract tumors (UTT) by Ramos, J, Casey, M, Bamias, A, De Giorgi, U, Bellmunt, J, Harshman, L, Ladoire, S, Wong, Y.N, Alva, A, Necchi, A, Recine, F, Vaishampayan, U, Niegisch, G, Pal, S, Crabb, S, Golshayan, A, Srinivas, S, Rosenberg, J, Galsky, M, Yu, E

Get full text

2619 Patterns and potential benefit of adjuvant chemotherapy for residual muscle invasive disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC) by Harshman, L, Werner, L, Wong, Y.N, Yu, E, Alva, A, Crabb, S, Powles, T, Rosenberg, J, Baniel, J, Vaishampayan, U, Berthold, D, Ladoire, S, Hussain, S, Milowsky, M, Agarwal, N, Necchi, A, Pal, S, Recine, F, Bellmunt, J, Galsky, M

Get full text